Observational Cohort Study of Patients With Metastatic Colorectal Cancer Initiating Chemotherapy in Combination With Bevacizumab (CONCERT)

摘要

The CONCERT cohort study (observational cohort study of patients with metastatic colorectal cancer initiating chemotherapy in combination with bevacizumab) was conducted to address French specificities on the use of bevacizumab in patients with metastatic colorectal cancer (mCRC) in everyday practice. CONCERT was a multicenter, prospective, observational study that included patients with mCRC, initiating bevacizumab combined with chemotherapy and followed up for <= 36 months. The median progression-free and overall survival duration observed in the real-life setting were in line with results of randomized clinical trials of bevacizumab plus chemotherapy for first-and second-line therapy for patients with mCRC.